Vallon Pharmaceuticals Announces Topline Results of its Pivotal SEAL Study for Lead Program, ADAIR, for the Treatment of ADHD
21 mars 2022 07h00 HE
|
Vallon Pharmaceuticals Inc.
– Study did not meet primary endpoint of significant reduction in Emax Drug Liking for ADAIR vs reference dextroamphetamine, although a trend in favor of ADAIR was observed (p=0.16) – All...
Vallon Pharmaceuticals Announces Achievement of Last Patient Last Visit in Pivotal SEAL Study for Lead Program, ADAIR
23 déc. 2021 08h05 HE
|
Vallon Pharmaceuticals Inc.
- Topline results from pivotal SEAL study expected in Q1 2022 - If approved, ADAIR will target the growing Adderall® segment of the ~$9 billion U.S. ADHD market PHILADELPHIA, PA, Dec. ...